Information  X 
Enter a valid email address

Astrazeneca PLC OrdShs USD0.25 (AZN)

Date Time Source Announcement
14 Feb 2019 7:00 am
RNS
AstraZeneca Full-Year and Q4 2018 Results
06 Feb 2019 7:00 am
RNS
US FDA grants Fasenra Orphan Drug Designation
05 Feb 2019 7:05 am
RNS
US FDA grants Breakthrough Therapy Designation
  7:00 am
RNS
EMA grants PRIME eligibility for MEDI8897
01 Feb 2019 3:00 pm
RNS
Total Voting Rights
  1:17 pm
RNS
Forxiga receives positive EU CHMP opinion
25 Jan 2019 2:00 pm
RNS
Completion of divestment of US Synagis rights
07 Jan 2019 1:00 pm
RNS
AstraZeneca announces organisational changes
02 Jan 2019 3:00 pm
RNS
Total Voting Rights
20 Dec 2018 1:47 pm
RNS
Bevespi Aerosphere approved in the EU for COPD
  7:05 am
RNS
Lynparza meets primary endpoint in SOLO-3 trial
  7:00 am
RNS
Phase III ROCKIES and OLYMPUS roxadustat trials
19 Dec 2018 6:31 pm
RNS
FDA approves Lynparza as 1L maintenance therapy
18 Dec 2018 9:09 am
RNS
Roxadustat approved in China for the treatment of
14 Dec 2018 7:00 am
RNS
Directorate Change
07 Dec 2018 7:00 am
RNS
Update on the Phase III EAGLE trial of Imfinzi
06 Dec 2018 7:00 am
RNS
Divestment of rights to Covis completed
04 Dec 2018 3:00 pm
RNS
Director/PDMR Shareholding
03 Dec 2018 4:00 pm
RNS
Block listing Interim Review
  4:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Gr?nenthal Agreement for Nexium, Vimovo Completed
26 Nov 2018 7:00 am
RNS
US FDA grants Fasenra ODD for EGPA
16 Nov 2018 7:00 am
RNS
AstraZeneca provides update on Phase III MYSTIC
13 Nov 2018 7:00 am
RNS
AstraZeneca to divest US Synagis rights to Sobi
12 Nov 2018 7:05 am
RNS
US FDA accepts regulatory submission for Lynparza
  7:00 am
RNS
Farxiga significantly reduced hospitalisation for
08 Nov 2018 7:00 am
RNS
AZN: Year-to-Date and Q3 2018 Results
06 Nov 2018 7:00 am
RNS
Divestment of rights to Covis Pharma
01 Nov 2018 3:00 pm
RNS
Total Voting Rights
31 Oct 2018 9:45 am
RNS
Additional financial information-Gr?nenthal deal
30 Oct 2018 7:00 am
RNS
Gr?nenthal Agreement for rights to Nexium, Vimovo
23 Oct 2018 7:00 am
RNS
AstraZeneca Extends Innate Pharma Collaboration
22 Oct 2018 7:00 am
RNS
Lynparza shows 70% reduction in PFS ovarian cancer
19 Oct 2018 1:09 pm
RNS
CHMP positive opinion Bevespi Aerosphere
16 Oct 2018 7:00 am
RNS
FDA Orphan Drug for Lynparza in pancreatic cancer
01 Oct 2018 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Atacand Agreement with Cheplapharm Completed
28 Sep 2018 4:00 pm
RNS
Previous Announcement Regarding Appointment Of NED
25 Sep 2018 1:15 pm
RNS
Overall survival data for Imfinzi: Stage III NSCLC
24 Sep 2018 4:10 pm
RNS
EMA approves AZ's Imfinzi for Stage III NSCLC
  7:00 am
RNS
Farxiga gets positive result in DECLARE-TIMI 58
14 Sep 2018 7:00 am
RNS
FDA approves AZ's Lumoxiti in hairy cell leukaemia
07 Sep 2018 7:00 am
RNS
Tezepelumab FDA Breakthrough Therapy Designation
06 Sep 2018 7:00 am
RNS
Directorate Change
03 Sep 2018 3:00 pm
RNS
Total Voting Rights
31 Aug 2018 7:00 am
RNS
AstraZeneca Update on Anifrolumab in SLE
30 Aug 2018 7:00 am
RNS
EC approves Bydureon BCise device for T2 diabetes
23 Aug 2018 7:00 am
RNS
AstraZeneca PIIIb trial update for Bevespi in COPD
21 Aug 2018 7:00 am
RNS
AZ's Tagrisso approved in Japan for 1st-line NSCLC
15 Aug 2018 7:00 am
RNS
AstraZeneca prices a $3bn bond issue
03 Aug 2018 7:00 am
RNS
EMA grants OD for selumetinib in NF1
01 Aug 2018 3:00 pm
RNS
Total Voting Rights
27 Jul 2018 2:00 pm
RNS
CHMP recommends Imfinzi for Stage III nsclc
26 Jul 2018 7:00 am
RNS
AZN: H1 2018 Results
24 Jul 2018 7:00 am
RNS
Atacand to be divested to Cheplapharm in Europe
18 Jul 2018 4:11 pm
RNS
Holding(s) in Company
  4:11 pm
RNS
Holding(s) in Company
  12:00 pm
RNS
Holding(s) in Company
02 Jul 2018 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Lynparza approved in Japan for BRCAm breast cancer
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t